HealthcareServices

Global Acute Kidney Injury Market Report 2026: Emerging Trends and Growth Scenarios

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the acute kidney injury market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Acute Kidney Injury Market by the end of 2030?

The acute kidney injury market has shown substantial growth in recent years. It is anticipated to increase from $5.72 billion in 2025 to $6.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. This historical growth can be linked to factors such as restricted availability of advanced renal care, an increasing prevalence of comorbidities including diabetes and hypertension, expanding hospital infrastructure, the utilization of conventional dialysis techniques, and greater awareness of AKI complications.

The market for acute kidney injury is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $7.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this growth during the projected timeframe include progress in renal replacement therapies, the creation of new nephroprotective medications, the increase in ambulatory surgical centers, the growing utilization of biomarkers for early diagnosis, and the incorporation of AI-based monitoring systems into kidney care. Key trends anticipated for this period encompass a wider acceptance of dialysis and drug treatments, the escalating global occurrence of acute kidney injury, an intensified emphasis on early diagnosis and biomarker advancements, the broadening of urinary implant uses, and the incorporation of less invasive methods in acute kidney injury management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21079&type=smp

What Drivers Are Shaping Future Opportunities In The Acute Kidney Injury Market?

The rising occurrence of diabetes is projected to fuel the expansion of the acute kidney injury market in the coming years. Diabetes encompasses various metabolic conditions marked by elevated blood sugar, resulting from either insufficient insulin production by the body or inadequate cellular response to insulin. This increasing prevalence of diabetes stems from factors like growing obesity rates, unhealthy eating habits, inactive lifestyles, an aging demographic, and improved detection and diagnosis. Acute kidney injury induces metabolic and inflammatory alterations capable of affecting insulin resistance and glucose regulation, indicating an intricate relationship that could influence the advancement and treatment of diabetes. As an illustration, in March 2024, data from the Office for Health Improvement & Disparities, a UK-based government body, revealed that from March 2022 to March 2023, there was a 22% increase in the proportion of individuals with type 1 diabetes receiving all eight suggested care processes, and a 21% rise for those with type 2 diabetes. Concurrently, the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever documented by the National Diabetes Audit (NDA). Consequently, the heightened incidence of diabetes is propelling the expansion of the acute kidney injury market.

Which Segment Groups Are Influencing The Acute Kidney Injury Market?

The acute kidney injury market covered in this report is segmented –

1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury

2) By Treatment Type: Renal Replacement Therapy (RRT), Pharmacological Management, Supportive and Conservative Management, Obstruction-Relief Interventions

3) By End User: Hospitals, Dialysis Centers, Specialty Clinics, Other End Users

Subsegments:

1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome

2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract

3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury

What Trends Are Driving The Growth Trajectory Of The Acute Kidney Injury Market?

Leading companies in the acute kidney injury (AKI) market are prioritizing the acquisition of regulatory approvals to expand their product portfolios and introduce new therapeutic solutions. Regulatory approvals signify the official permission granted by governing bodies, such as the FDA or EMA, for a product to be sold and marketed after it meets required safety, efficacy, and quality benchmarks. For example, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology firm, secured FDA authorization to commence a Phase II clinical trial for its key drug candidate, MTX652, aimed at acute kidney injury (AKI) in individuals at high risk following cardiac surgery. This asset is designed to target crucial pathways involved in kidney damage and repair, seeking to diminish inflammation, avert further renal deterioration, and foster recovery. The trial’s unique characteristic is its focus on employing novel therapeutic mechanisms to address the core molecular causes of AKI, which could provide more effective treatment options compared to existing interventions. The Phase II trial will evaluate MTX652’s safety, efficacy, and pharmacokinetics, gathering essential data that could support broader clinical acceptance and potential approval.

Who Are The Prominent Global Companies Shaping The Acute Kidney Injury Market Landscape?

Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Acute Kidney Injury Market?

North America was the largest region in the acute kidney injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Acute Kidney Injury Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21079&type=smp

Browse Through More Reports Similar to the Global Acute Kidney Injury Market 2026, By The Business Research Company

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Kidney Dialysis Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report

Acute Spinal Cord Injury Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-spinal-cord-injury-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795